

Works by Ariel Fernandez involved in research misconduct allegations by ORI

- A. Crespo, A. Fernandez. "Induced Disorder in Protein–Ligand Complexes as a Drug-Design Strategy." *Molecular Pharmaceutics*, 5(3), 430-437, 2008, doi: 10.1021/mp700148h
([Correction in 2008](#). [Correction in 2009](#). [Correction in 2010](#))
- A. Fernandez, S. Sessel. "Selective antagonism of anticancer drugs for side-effect removal," *Trends in Pharmacological Sciences*, 30(8):403-10, 2009, doi: 10.1016/j.tips.2009.06.001
- A. Fernandez. "Incomplete Protein Packing as a Selectivity Filter in Drug Design," *Structure*, 13(12), 1829-36, 2005 doi:10.1016/j.str.2005.08.018
- A. Fernandez, R. Scott, R.S. Berry. Packing defects as selectivity switches for drug-based protein inhibitors," *PNAS*, 103(2), 323-8, 2006, doi: 10.1073/pnas.0509351102 ([Retracted in 2006](#))
- A. Fernandez, S. Maddipati. "A Priori Inference of Cross Reactivity for Drug-Targeted Kinases," *Journal of Medicinal Chemistry*, 49(11), 3092-100, 2006, doi: 10.1021/jm060163j
- A. Fernandez, A. Crespo. "Wrapping technology and the enhancement of specificity in cancer drug treatment," *Frontiers in Bioscience*, 12(10), 3617-27, 2007, doi: 10.2741/2338
- A. Crespo, X. Zhang, A. Fernandez. "Redesigning Kinase Inhibitors to Enhance Specificity," *Journal of Medicinal Chemistry*, 51(6), 4890-8, 2008, doi: 10.1021/jm800453a
- A. Fernandez, A. Crespo, S. Maddipati, R. Scott. Bottom-Up Engineering of Peptide Cell Translocators Based on Environmentally Modulated Quadrupole Switches," *ACS Nano*, 2(1), 61-8, 2008, doi: 10.1021/jm800453a ([Correction in 2012](#))
- A. Fernandez. "Incomplete Protein Packing as a Selectivity Filter in Drug Design," *Structure Addendum* 14(5), 947, 2006
- S. Maddipati, A. Fernandez. "Peptide translocators with engineered dehydration-prone hydrogen bond," *The Journal of Chemical Physics*, 126(6), 061102, 2007, doi: 10.1063/1.2698277
- A. Fernandez, A. Sanguino; Z. Peng; A. Crespo; E. Ozturk; X. Zhang; S. Wang; W. Bornmann; G. Lopez-Berestein. "Rational Drug Redesign to Overcome Drug Resistance in Cancer Therapy: Imatinib Moving Target" *Cancer Research* 67(9), 4028-4033, 2007, doi: 10.1158/0008-5472.CAN-07-0345 ([Correction in 2013](#))